搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Vibrio cholerae serotype O1 Serine--tRNA ligase (serS) CSB-YP864646VEX
CSB-EP864646VEX
CSB-BP864646VEX
CSB-MP864646VEX
CSB-EP864646VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Uridine kinase (udk) CSB-YP864647VEX
CSB-EP864647VEX
CSB-BP864647VEX
CSB-MP864647VEX
CSB-EP864647VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Regulatory protein luxO (luxO) CSB-YP864648VEX
CSB-EP864648VEX
CSB-BP864648VEX
CSB-MP864648VEX
CSB-EP864648VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Glutamine--tRNA ligase (glnS), partial CSB-YP864649VEX
CSB-EP864649VEX
CSB-BP864649VEX
CSB-MP864649VEX
CSB-EP864649VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Phosphocarrier protein HPr (ptsH) CSB-YP864650VEX
CSB-EP864650VEX
CSB-BP864650VEX
CSB-MP864650VEX
CSB-EP864650VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Lipoyl synthase (lipA) CSB-YP864651VEX
CSB-EP864651VEX
CSB-BP864651VEX
CSB-MP864651VEX
CSB-EP864651VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 NADPH-dependent 7-cyano-7-deazaguanine reductase (queF) CSB-YP864652VEX
CSB-EP864652VEX
CSB-BP864652VEX
CSB-MP864652VEX
CSB-EP864652VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 1-deoxy-D-xylulose-5-phosphate synthase (dxs), partial CSB-YP864653VEX
CSB-EP864653VEX
CSB-BP864653VEX
CSB-MP864653VEX
CSB-EP864653VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 UPF0253 protein VC_0872 (VC_0872) CSB-YP864654VEX
CSB-EP864654VEX
CSB-BP864654VEX
CSB-MP864654VEX
CSB-EP864654VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Probable oxaloacetate decarboxylase gamma chain 2 (oadG2), partial CSB-YP864655VEX1
CSB-EP864655VEX1
CSB-BP864655VEX1
CSB-MP864655VEX1
CSB-EP864655VEX1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 GMP synthase [glutamine-hydrolyzing] (guaA), partial CSB-YP864656VEX
CSB-EP864656VEX
CSB-BP864656VEX
CSB-MP864656VEX
CSB-EP864656VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Cysteine desulfurase (iscS) CSB-YP864657VEX
CSB-EP864657VEX
CSB-BP864657VEX
CSB-MP864657VEX
CSB-EP864657VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Polyphosphate kinase (ppk), partial CSB-YP864658VEX
CSB-EP864658VEX
CSB-BP864658VEX
CSB-MP864658VEX
CSB-EP864658VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Norspermidine sensor (nspS) CSB-YP864659VEX
CSB-EP864659VEX
CSB-BP864659VEX
CSB-MP864659VEX
CSB-EP864659VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Anhydro-N-acetylmuramic acid kinase (anmK) CSB-YP864660VEX
CSB-EP864660VEX
CSB-BP864660VEX
CSB-MP864660VEX
CSB-EP864660VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Lipoprotein signal peptidase (lspA), partial CSB-YP864661VEX1
CSB-EP864661VEX1
CSB-BP864661VEX1
CSB-MP864661VEX1
CSB-EP864661VEX1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Ribosome-binding factor A (rbfA) CSB-YP864662VEX
CSB-EP864662VEX
CSB-BP864662VEX
CSB-MP864662VEX
CSB-EP864662VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Glutamate-1-semialdehyde 2,1-aminomutase (hemL) CSB-YP864663VEX
CSB-EP864663VEX
CSB-BP864663VEX
CSB-MP864663VEX
CSB-EP864663VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 3-methyl-2-oxobutanoate hydroxymethyltransferase (panB) CSB-YP864664VEX
CSB-EP864664VEX
CSB-BP864664VEX
CSB-MP864664VEX
CSB-EP864664VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 50S ribosomal protein L19 (rplS) CSB-YP864665VEX
CSB-EP864665VEX
CSB-BP864665VEX
CSB-MP864665VEX
CSB-EP864665VEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>